68363-44-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-((2-Benzhydrylphenyl)amino)thiazol-4-yl)-2-oxoacetic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those with potential antibacterial properties. Its unique structure allows for the development of novel drugs that can target specific bacterial strains and combat antibiotic resistance.
Used in Antibacterial Applications:
2-(2-((2-Benzhydrylphenyl)amino)thiazol-4-yl)-2-oxoacetic acid is used as a precursor in the preparation and study of antibacterial agents, such as acetohydroxamoylethyliminoacetylcephalosporins. These agents exhibit potent antibacterial activity, making them valuable in the development of new antibiotics to address the growing issue of drug-resistant bacteria.

Upstream product

• 68363-43-9 ethyl 2-oxo-2-(2-(tritylamino)thiazol-4-yl)acetate 
• 64987-08-2 ethyl 2-(2-aminothiazol-4-yl)glyoxylate 
• 76-83-5 trityl chloride 

Downstream Products

• 941286-37-9 (Z)-3-acetyl-1-(4-methoxyphenyl)-8-(2-(tritylamino)thiazol-4-yl)-2,6-dioxa-3,7-diazanon-7-en-9-oic acid 
• 136248-54-9 [(Z)-2,2-Dimethyl-benzo[1,3]dioxol-5-ylmethoxyimino]-[2-(trityl-amino)-thiazol-4-yl]-acetic acid 
• 133076-31-0 p-methoxybenzyl 7-<(Z)-2-(2-tritylaminothiazol-4-yl)-2-(2-(3-diphenylmethoxy-4-pyridon-1-yl)-1-diphenylmethoxycarbonylethoxyimino)acetamido>-3-(1,2,3-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate 
• 133076-30-9 p-methoxybenzyl 7-<(Z)-2-(2-tritylaminothiazol-4-yl)-2-(3-(3-diphenylmethoxy-4-pyridon-1-yl)-3-diphenylmethoxycarbonylpropoxyimino)acetamido>-3-(1,2,3-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate 
• 133076-32-1 p-methoxybenzyl 7-<(Z)-2-(2-tritylaminothiazol-4-yl)-2-(2-(3-diphenylmethoxy-4-pyridon-1-yl)ethoxyimino)acetamido>-3-(1,2,3-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate 
• 114875-61-5 (Z)-2-(((1,5-bis(benzhydryloxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)imino)-2-(2-(tritylamino)thiazol-4-yl)acetic acid 
• 68363-45-1 7[(2-Triphenylmethylamino-thiazol-4-yl)-glyoxylamido]-cephalosporanic acid 
• 941286-29-9 (2Z)-3-{[5-(diphenylmethoxy)-1-methyl-4-oxo(2-hydropyridyl)]methoxy}-2-{2-[(triphenylmethyl)amino](1,3-thiazol-4-yl)}-3-azaprop-2-enoic acid 
• 73562-94-4 (Z)-2-(1-t-Butoxycarbonylcycloprop-1-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetic acid 
• 92591-21-4 (Z)-α-(2-tritylamino-4-thiazolyl)-α-[(2-tritylamino-4-thiazolyl)methoxyimino]acetic acid 

Relevant academic research and scientific papers

Synthesis and antibacterial evaluation against resistant Gram-negative bacteria of monobactams bearing various substituents on oxime residue

Based on the structural characteristics of aztreonam (AZN) and its target PBP3, a series of new monobactam derivatives bearing various substituents on oxime residue were prepared and evaluated for their antibacterial activities against susceptible and res

MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION

Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated

DEUTERATED O-SULFATED BETA-LACTAM HYDROXAMIC ACIDS AND DEUTERATED N-SULFATED BETA-LACTAMS

Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.

OXAMAZIN ANTIBIOTICS

Disclosed herein are oxamazin monobactam compounds and their use as antibiotics resistant to degradation by β-lactamases. Also disclosed are pharmaceutical compositions containing the compounds and methods of synthesis.

OXAMAZIN ANTIBIOTICS

Disclosed herein are oxamazin monobactam compounds and their use as antibiotics resistant to degradation by β-lactamases. Also disclosed are pharmaceutical compositions containing the compounds and methods of synthesis.

NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Cephem derivative

Cephem derivatives of the general formula STR1 in which the R2 O group is in the syn-position, a process for their manufacture and pharmaceutical formulations which are active against bacterial infections and contain these compounds.